Favipiravir
Favipiravir
Favipiravir, also known as T-705, Avigan, or favilavir is an antiviral drug being developed by Toyama Chemical (Fujifilm group) of Japan with activity against many RNA viruses. Like certain other experimental antiviral drugs (T-1105 and T-1106), it is a pyrazinecarboxamide derivative. In experiments conducted in animals Favipiravir has shown activity against influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses.[1] Activity against enteroviruses[2] and Rift Valley fever virus has also been demonstrated.[3] Favipiravir has showed limited efficacy against Zika virus in animal studies, but was less effective than other antivirals such as MK-608.[4] The agent has also shown some efficacy against rabies,[5] and has been used experimentally in some humans infected with the virus.[6]
In February 2020, Favipiravir was being studied in China for experimental treatment of the emergent COVID-19 (novel coronavirus) disease.[7][8] On March 17, Chinese officials suggested the drug had been effective in treating COVID in Wuhan and Shenzhen.[9][10]
B B K NEWS
#manishkansara
#manishkansara
OWNER
Manish Kansara
635291895
⚜️⚜️⚜️⚜️⚜️⚜️⚜️⚜️⚜️⚜️⚜️⚜️
Comments
Post a Comment